Affitech AS Renews Exclusive Worldwide Phage Display License From German Cancer Research Center (DKFZ)

CHICAGO--(BUSINESS WIRE)--April 9, 2006--The human antibody company, Affitech AS, announced today at BIO 2006 that they have renewed an exclusive worldwide licensing agreement with DKFZ (German Cancer Research Center) of Heidelberg, Germany for the antibody library display patents, otherwise known as "Breitling" IP family. These patents cover the use of full-length pIII phage protein as a scaffold in a phagemid vector, and are one of the fundamental patents for the phagemid display of antibody, antibody fragments and proteins. As the antibody therapeutic market continues to grow with a record number of candidates moving through pre-clinical and clinical trials, Affitech anticipates that all serious entrants in the antibody field will consider the use of these patents. This is backed by the fact that over the past couple of years, Affitech has successfully negotiated cross-licensing agreements involving Breitling IP with leading antibody companies such as Dyax and Xoma.
MORE ON THIS TOPIC